Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: Comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy

Drugs under Experimental and Clinical Research

Volumn 26, Issue 1, 2000, Pages 1-5

  Takemoto, Y ^a   Wada, H ^a   Takatsuka, H ^a   Okamoto, T ^a   Kakishita, E ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ALKALOID; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; STEM CELL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPHILS; PREDNISOLONE; VINCRISTINE;

EID: 0034068051     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Philpott N.J., Prue R.L., Marsh J.C.W., et al. G-CSF mobilized CD34-peripheral blood stem cells are significantly less apototic than unstimulated peripheral blood CD34+ cells: Role of G-CSF as survival factor. Br. J. Haematol., 97, 146, 1997.
2. Zimmerman T.M., Mick R., Myers S., et al. Source of stem cells impacts on hematopoietic recovery after high-close chemotherapy. Bone Marrow Transplant, 15, 923, 1995.
3. Nissen C., Carbonare V.D., Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated RG-CSF. Drug Invest., 7, 346, 1994.
4. Hoglund M., Smedmyr B., Bengteson M., et al. Mobilization of CD34+ cells by glycosylated and non-glycosylated G-CSF in healthy volunteers - a comparative study. Eur. J. Haematol., 59, 177, 1997.
5. Weaver C.H., Schwartzberg L.S., Zhen B., et al. Mobilization cf peripheral blood stem cells with docetaxel and cyciophosphamide (CY) in patients with metastatic breast cancer: A randomized trial of 3 vs. 4 g/m-of CY. Bone Marrow Transplant, 23, 421, 1999.
6. Fennelly D., Schneider J., Spriggs D., et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J. Clin. Oncol., 13, 1160, 1995.
7. Oh-eda M., Hasegawa M., Hattori K., et al. O-linked sugar chain of human granulocyte colony-stimulating factor protect it against polymerization and denaturation allowing it to retain its biological activity. J. Biol. Chem., 265, 11432, 1990.
8. Okabe M., Asano M., Kuga T., et al. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. Blood 75, 1990.
9. Brugger W., Bross K.J., Glatt M., et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood, 83, 636, 1994.